Phillip A. Sharp Sells 11,250 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Alnylam Pharmaceuticals Trading Up 1.2 %

Shares of NASDAQ:ALNY opened at $278.76 on Monday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock has a market capitalization of $35.95 billion, a PE ratio of -106.40 and a beta of 0.34. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a fifty day moving average price of $247.13 and a 200 day moving average price of $260.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same quarter last year, the company posted $1.15 earnings per share. The business’s revenue was down 33.3% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Huntington National Bank raised its holdings in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares during the period. Hollencrest Capital Management acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $29,000. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $33,000. Washington Trust Advisors Inc. acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $42,000. Finally, True Wealth Design LLC increased its position in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of recent research reports. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Bank of America raised their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $298.61.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.